Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Introduction: Anti‐EGFR agents are standard treatments for patients with EGFR‐mutant advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti–programmed death 1 immunotherapy pembrolizumab was evaluated in the phase 1/2 KEYNOTE‐021 study (NCT02039674). Methods: Adults with previously untreated stage IIIB/IV EGFR‐mutant NSCLC were treated with pembrolizumab 2 mg/kg intravenously every 3 weeks plus oral erlotinib 150 mg daily in cohort E or oral gefitinib 250 mg daily in cohort F, using a 3 + 3 design with cohort expansion. rTumor response was evaluated per Response Evaluation Criteria in Solid Tumors version 1.1 by blinded independent central review. The primary objective was determination of a recommended phase 2 dose. Results: Twelve patients enrolled to receive pembrolizumab plus erlotinib and seven to receive pembrolizumab plus gefitinib. No dose‐limiting toxicities or grade 5 events occurred. Pembrolizumab plus erlotinib was feasible, with adverse events similar to those expected for monotherapy. However, pembrolizumab plus gefitinib was not feasible due to grade 3/4 liver toxicity in five of seven patients (71.4%), leading to permanent treatment discontinuation in four patients. The most frequently occurring treatment‐related adverse events with pembrolizumab plus erlotinib were rash (50.0%), dermatitis acneiform, diarrhea, hypothyroidism, and pruritus (33.3% each). The objective response rate was 41.7%, including response in all four patients with programmed death ligand 1 expression 50% or greater. Conclusions: Although pembrolizumab plus gefitinib was not feasible, the toxicity profile observed with pembrolizumab plus erlotinib suggests combining immunotherapy with anti‐EGFR therapy is feasible. Pembrolizumab plus erlotinib did not improve objective response rate compared with previous monotherapy studies; further evaluation would be necessary to evaluate potential effects on other efficacy outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 2×
“Pembrolizumab plus gefitinib was not deemed feasible for phase 2 evaluation due to liver toxicity, in line with previous clinical studies and a recent meta-analysis.(5,8) Liver toxicity has also been reported in studies with other anti PD-(L)1 agents as monotherapy and in combination with EGFR TKIs.”
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“monotherapy studies.(6,11,12) Although the ORR in patients with PD-L1 TPS greater than or equal to 50% (4 of 4; 100%) is noteworthy, as was the durability of response in this group, there were too few patients to draw meaningful conclusions regarding possible additive or synergistic antitumor effects compared with mon…”
Self-citationOsimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 1×
“Additionally, recent studies have provided support for newly developed EGFR inhibitors in certain subsets of patients.(14,15) Overall, in the context of incrementally efficacious targeted therapy for EGFR-mutant NSCLC, other mechanisms of immune escape may need to be investigated.”
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · cited 2×
“monotherapy studies.(6,11,12) Although the ORR in patients with PD-L1 TPS greater than or equal to 50% (4 of 4; 100%) is noteworthy, as was the durability of response in this group, there were too few patients to draw meaningful conclusions regarding possible additive or synergistic antitumor effects compared with mon…”
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citation
Cited by
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 508
Self-citationAntitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 264
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
Metadata
- Authors
- Yang, J. C.-H., Gadgeel, S. M., Sequist, L. V., Wu, C.-L., Papadimitrakopoulou, V. A., Su, W.-C., Fiore, J., Saraf, S., Raftopoulos, H., & Patnaik, A.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 14
- Issue
- 3
- Pages
- 553-559
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2903379674
- Cited by
- 180
- References
- 6
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. https://app.cochat.ai/papers/10.1016/j.jtho.2018.11.028
- The paper
- Yang, J. C.-H., Gadgeel, S. M., Sequist, L. V., Wu, C.-L., Papadimitrakopoulou, V. A., Su, W.-C., Fiore, J., Saraf, S., Raftopoulos, H., & Patnaik, A. (2019). Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.11.028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.